

**AVATROMBOPAG tablets (Doptelet® ▼)
for treating severe thrombocytopenia in adults with chronic liver disease having
planned invasive procedures**

The Pan Mersey Area Prescribing Committee recommends the prescribing of AVATROMBOPAG tablets (Doptelet® ▼), by specialists only, for treating severe thrombocytopenia in adults with chronic liver disease having planned invasive procedures in accordance with NICE TA626.

RED

NICE technology appraisal (TA) 626 recommends avatrombopag, within its marketing authorisation, as an option for treating severe thrombocytopenia (defined as a platelet count of below 50,000 platelets per microlitre of blood) in adults with chronic liver disease having planned invasive procedures.^[1]

- > The recommended dosage of avatrombopag is based on the patient's platelet count:
 - below 40,000 platelets per microlitre of blood – 60 mg once daily
 - 40,000 to below 50,000 platelets per microlitre of blood – 40 mg once daily^[1]
- > Dosing should begin 10 to 13 days prior to the planned procedure. The patient should undergo their procedure 5 to 8 days after the last dose of avatrombopag.^[2]
- > Avatrombopag should not be taken for more than 5 days.^[2]

Prescribing and monitoring should be retained by either a specialist in haematology or gastroenterology, depending on the procedure.

NICE does not expect this guidance to have a significant impact on resources; that is, the resource impact of implementing the recommendations will be less than £5 million per year in England (or £9,000 per 100,000 population).

Avatrombopag is a further treatment option and due to this, the overall incremental cost of treatment is not deemed to be significant. The addition of avatrombopag in the treatment pathway may help reduce the need for platelet transfusions. It may also help increase the time in which procedures can be scheduled and reduce hospital stays.

References

1. National Institute for Health and Care Excellence. Technology Appraisal 626; [Avatrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure](#), 24 June 2020. Accessed online 24 June 2020.
2. European Medicines Agency. EPAR Product Information, Doptelet; [Annex I, Summary of Product Characteristics](#), 27 January 2020. Accessed online 22 June 2020.

Note: Patients who are not eligible for treatment under this statement may be considered on an individual basis where their GP or consultant believes exceptional circumstances exist that warrant deviation from the rule of this policy. In this situation, follow locally defined processes.